Key result
Epicardial catheter ablation eliminated arrhythmogenic substrates, rendering 96% of symptomatic Brugada syndrome patients free of recurrent ventricular fibrillation without anti-arrhythmic drugs.
Why the study?
To discuss the role of catheter ablation in treating life-threatening ventricular arrhythmias associated with Brugada syndrome by presenting recent findings of arrhythmogenic substrate and underlying mechanisms.
Does catheter ablation prevent recurrent ventricular fibrillation episodes in patients with Brugada syndrome?
Does catheter ablation prevent recurrent ventricular fibrillation episodes in patients with Brugada syndrome?
p-value: p=<0.01
Catheter ablation serves as an important and effective therapeutic modality for symptomatic Brugada syndrome patients to prevent recurrent ventricular fibrillation.
May reduce recurrent VF in symptomatic Brugada syndrome; leaves open confirmation by randomized trials.
PURPOSE OF REVIEW: To discuss the role of catheter ablation in treating life-threatening ventricular arrhythmias associated with Brugada syndrome (BrS), by presenting recent findings of BrS arrhythmogenic substrate, mechanisms underlying ventricular arrhythmias, and how they can be treated with catheter ablation. RECENT FINDINGS: Almost three decades ago when the clinical entity of Brugada syndrome (BrS) was described in patients who had abnormal coved-type ST elevation in the right precordial EKG leads in patients who had no apparent structural heart disease but died suddenly from ventricular fibrillation. Since its description, the syndrome has galvanized explosive research in this field over the past decades, driving major progress toward better understanding of BrS, gaining knowledge of the genetic pathophysiology and risk stratification of BrS, and creating significant advances in therapeutic modalities. One of such advances is the ability for electrophysiologists to map and identify the arrhythmogenic substrate sites of BrS, which serve as good target sites for catheter ablation. Subsequently, several studies have shown that catheter ablation of these substrates normalizes the Brugada ECG pattern and is very effective in eliminating these substrates and preventing recurrent VF episodes. Catheter ablation has become an important addition for treatment of symptomatic BrS patients with recurrent VT/VF episodes.
No takes yet. Share an insight, caveat, or question.
Chokesuwattanaskul et al. (2021) conducted a review in Brugada syndrome (n=54). Epicardial substrate catheter ablation was evaluated on Freedom from ventricular fibrillation (VF) without anti-arrhythmic drugs after repeat catheter ablation (p=<0.01). Epicardial catheter ablation eliminated arrhythmogenic substrates, rendering 96% of symptomatic Brugada syndrome patients free of recurrent ventricular fibrillation without anti-arrhythmic drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: